Atai Life Sciences NVNASDAQ: ATAI

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation:

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin.

Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its application for MDMA-assisted therapy for post-traumatic stress disorder before the Food and Drug Administration (FDA) Advisory Committee (AdCom).

Atai Life Sciences has announced that Florian Brand will be stepping down as CEO and co-founder Srinivas Rao will take over the role. Rao, currently the company's chief scientific officer, will become co-CEO in June and will fully transition into the CEO position by the end of the year.

Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced that the results of Beckley Psytech's Phase 1 study on their intranasal benzoate salt formulation of 5-MeO-DMT, BPL-003, have been published in The Journal of Psychopharmacology. The study examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of BPL-003 in 44 healthy volunteers who were divided into seven groups and administered a single dose of BPL-003 ranging from 1 mg to 12 mg, or a placebo, along with psychological support.

Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has made significant progress in developing its unique mental health treatments in 2023, specifically focusing on psychedelic therapies for depression. CEO and co-founder Florian Brand spoke with Proactive about the company's recent achievements, positive clinical trial outcomes, ongoing research initiatives, and upcoming developments in the psychedelics industry.

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based therapies targeting several mental health conditions. Recent clinical highlights included positive results from Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of 5-MeO-DMT, in patients with treatment-resistant depression.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech's Phase 2a study of its novel DMT formulation BPL-003 in patients with treatment-resistant depression. The biopharmaceutical company said during the open-label study, a single 10mg dose of BPL-003 – a novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) – was administered intranasally along with psychological support and induced a rapid antidepressant response in 55% of patients the day after dosing.